ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,700.30
-0.31%
S&P ASX All Technology
3,078.20
-0.47%
Brent Oil
82.315
0.23%
US Dollar vs AUD
1.51375
0.00%
Bitcoin
65,833.50
-1.21%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) News

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateTimeSourceHeadlineSymbolCompany
17/06/202420:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
17/06/202420:00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
04/06/202422:00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
04/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
04/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
04/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
03/06/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/06/202422:00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
31/05/202406:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
29/05/202406:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
29/05/202406:01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
15/05/202400:00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
08/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
08/05/202422:00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202423:00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
07/03/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/03/202400:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/03/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/03/202400:00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
29/02/202408:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
29/02/202408:01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
24/02/202409:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202412:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202412:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202412:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
16/02/202412:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
30/01/202400:00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
10/01/202400:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Your Recent History

CCOM
SILVER
SILVER
NYSE
MCD
McDonalds
ASX
TLS
Telstra
ASX
BHP
BHP
ASX
AMP
AMP
SPI
SP500
S&P 500
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
NYSE
VZ
Verizon Communications
FX
EURAUD
Euro vs AUD
ASX
WBC
Westpac Banking
ASX
WDC
Westfield
ASX
XJO
S&P ASX 200
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved